Microbrush reported on Wednesday the immediate availability of the US FDA-listed, ready-for-use, sterilized, nasopharyngeal test swab to meet the growing demand for COVID-19 testing requirements.
Manufactured in Grafton, Wisconsin, Microbrush's test swab from soft nylon fibers provides an improved patient experience over 3D-printed swabs. The swabs are individually packaged in a medical-grade pouch and are intended for clinical nasopharyngeal sample collection.
Microbrush is a subsidiary of Young Innovations Inc, a provider of equipment used by dentists, hygienists, dental assistants and consumers.
MaaT Pharma outlines potential Phase 3 development plan for MaaT013 after CHMP negative opinion
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Medtronic receives FDA clearance for LigaSure RAS Maryland instrument on Hugo system
VaxThera partners with Codagenix for next generation yellow fever vaccine advancement
MaaT Pharma receives negative CHMP trend vote for MaaT013
FDA approves Scholar Rock's ISEMBYLD to treat spinal muscular atrophy
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
US FDA grants orphan drug designation for Lundbeck's asedebart
Renova Pharmaceuticals launches first three US generic products